SEARCH

SEARCH BY CITATION

References

  • 1
    Israili ZH, Hernandez-Hernandez R, Valasco M. The future of antihypertensive treatment. Am J Ther. 2007;14:121134.
  • 2
    Rosamund W. Heart disease and stroke-2008 update. A report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation. 2008;17 e 25.
  • 3
    Svetkey LP, Simons-Morton DG, Proschan MA. Effect of the dietary approaches to stop hypertension diet and reduced sodium intake on blood pressure control. J Clin Hypertens. 2004;6:373381.
  • 4
    Young DB, Lin H, McCabe RD. Potassium’s cardiovascular protective mechanisms. Am J Physiol. 1995;268(4 Pt 2):R 825R 837.
  • 5
    INTERSALT Cooperative Research Group. INTERSALT: an international study of electrolyte excretion and blood pressure. Results for 24 hour urinary sodium and potassium excretion. BMJ. 1988;297:319328.
  • 6
    Efford J, Philips A, Thomsoon AG. Migration and geographic variations in blood pressure in Britain. BMJ. 1990;300:291295.
  • 7
    Appel LJ, Moore TH, Obarzanek E. A clinical trial of the effects of dietary patterns on blood pressure. Research Group. N Engl J Med. 1997;336:11171124.
  • 8
    Sacks FM, Svetkey LP, Vollmer WM. DASH-Sodium Collaborative Research Group. Effects on blood pressure or reduced dietary sodium and the Dietary Approaches to Stop Hypertension (DASH) diet. N Engl J Med. 2001;344:310.
  • 9
    Moore TJ, Conlin PR, Ard J. DASH (Dietary Approaches to Stop Hypertension) diet is effective treatment for stage 1 isolated systolic hypertension. Hypertension. 2001;38:155158.
  • 10
    Chobanian AV, Bakris GL, Black HR, et al.. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure: the JNC 7 report. JAMA. 2003;289:25602572.
  • 11
    Appel LJ, Brands ME, Daniels SR. Dietary approaches to prevent and treat hypertension: a scientific statement from the American Heart Association. Hypertension. 2006;47:296308.
  • 12
    Society of Hypertension-European Society of Cardiology Guidelines Committee. 2003 European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertens. 2003;21:10111063.
  • 13
    Whitworth JA; World Health Organization. International Society of Hypertension Writing Group. 2003 World Health Organization (WHO) International Society of Hypertension (ISH) statement on management of hypertension. J Hypertens. 2003;21:19831992.
  • 14
    Williams B, Poulter NR, Brown MJ. British Hypertension Society guidelines for hypertension management. 2004(BHS -IV): summary. BMJ. 2004;328: 634– 640.
  • 15
    Jee SH, Miller ER, Guallar E. The effect of magnesium supplementation on blood pressure: a meta-analysis of randomized clinical trials. Am J Hypertens. 2002;15:691696.
  • 16
    Touyz RM. Role of magnesium in the pathogenesis of hypertension. Mol Aspects Med. 2003;24:107136.
  • 17
    Resnick LM. Magnesium in the pathophysiology and treatment of hypertension and diabetes mellitus. Where are we in 1997? Am J Hypertens. 1997;10:368370.
  • 18
    Kawano Y, Matsuoka H, Takishita S, et al. Effects of magnesium supplementation in hypertensive patients: assessment by office, home, and ambulatory blood pressures. Hypertension. 1998;32:260265.
  • 19
    Witteman JC, Grobbee DE, Derkx FH, et al. Reduction of blood pressure with oral magnesium supplementation in women with mild to moderate hypertension. Am J Clin Nutr. 1994;60:129135.
  • 20
    Hatzistavri LS, Sarafidis PA, Georgianos PI, et al. Oral magnesium supplementation reduces ambulatory blood pressure in patients with mild hypertension. Am J Hypertens. 2001;22:10701075.
  • 21
    Sacks FM, Brown LE, Appel L. Combination of potassium, calcium and magnesium suplements in hypertension. Hypertension. 1995;26(6 Pt 1):950956.
  • 22
    Mizushima S, Cuppauccio FP, Nichols R. Dietary magnesium intake and blood pressure: a qualitative overview of the observational studies. J Hum Hypertens. 1998;12:447453.
  • 23
    Dickinson HO, Nicolson DJ, Campbell F. Potassium supplementation for the management of primary hypertension in adults. Cochrane Database Syst Rev. 2006;3:CD004641.
  • 24
    Haga H. Effects of dietary magnesium supplementation on diurnal variations of blood pressure and plasma Na+, K+- ATPase activity in essential hypertension. Jpn Heart J. 1992;33:785800.
  • 25
    Kisters K. Oral magnesium supplementation improves borderline hypertension. Magnes Res. 2011;24:1718.
  • 26
    Patki PS, SIngh J, Gokhale SV, et al. Efficacy of potassium and magnesium in essential hypertension: a double-blind placebo controlled, crossover study. BMJ. 1990;301:521523.
  • 27
    Houston MC. The importance of potassium in managing hypertension. Curr Hypertens Rep. 2011;13(4):309317.
  • 28
    McCarty MF. Complementary vascular-protective actions of magnesium and taurine: a rationale for magnesium taurate. Med Hypotheses. 1996;46:89100.
  • 29
    Yamori Y, Taquchi T, Mori H, et al. Low cardiovascular risks in the middle aged males and females excreting greater 24-hour urinary taurine and magnesium in 41 WHO-CARDIAC study populations in the world. J Biomed Sci. 2010;17(Suppl 1):S21.
  • 30
    Guerrero-Romero F, Rodriquez-Moran M. The effect of lowering blood pressure by magnesium supplementation in diabetic hypertensive adults with low serum magnesium levels: a randomized, double-blind placebo-controlled clinical trial. J Hum Hypertens. 2009;23:245251.
  • 31
    Rosanoff A. Magnesium supplements may enhance the effect of antihypertensive medication in stage 1 hypertensive subjects. Magnes Res. 2010;23:2740.
  • 32
    Wirell MP, Wester PO, Steqmayr BG. Nutritional dose of magnesium in hypertensive patients on beta blockers lowers systolic blood pressure: a double-blind, cross-over study. J Intern Med. 1994;236:189195.
  • 33
    Rudnicki M, Frolich A, Pilagaard K, et al. Comparsion of magnesium and methyldopa for the control of blood pressure in pregnancies complicated with hypertension. Gynecol Obstet Invest. 2000;49:231235.
  • 34
    Larsson SC, Virtamo J, Wolk A. Potassium, calcium and magnesium intakes and risk of stroke in women. Am J Epidemiol. 2011;174(1):3543.
  • 35
    Raffelmann T, Dorr M, Ittermann T, et al. Low serum magnesium concentrations predicts increase in left ventricular mass over 5 years independently of common cardiovascular risk factors. Atherosclerosis. 2010;213:563569.
  • 36
    Ohira T, Peacock JM, Iso H, et al. Serum and dietary magnesium and risk of ischemic stroke: the Atherosclerosis Risk in Communities Study. Am J Epidemiol. 2009;169:14371444.
  • 37
    Champagne CM. Magnesium in hypertension, cardiovascular disease, metabolic syndrome and other conditions: a review. Nutr Clin Pract. 2008;23:142151.
  • 38
    Hadjistavri LS, Sarafidis PA, Georgianos PI, et al. Beneficial effects of oral magnesium supplementation on insulin sensitivity and serum lipid profile. Med Sci Monit. 2010;16:CR307CR312.
  • 39
    Khan AM, Sullivan L, Mccabe E, et al. Lack of association between serum magnesium and the risks of hypertension and cardiovascular disease. Am Heart J. 2010;160:715720.
  • 40
    Barbagallo M, Dominguez LJ, Galioto A, et al. Oral magnesium supplementation improves vascular function in elderly diabetic patients. Magnes Res. 2010;23:131137.
  • 41
    Preuss HG. Diet, genetics and hypertension. J Am Coll Nutr. 1997;16:296305.
  • 42
    Das UN. Essential fatty acids: biochemistry, physiology and pathology. Biotechnol J. 2006;1:420439.
  • 43
    Das UN. Nutrients, essential fatty acids and prostaglandins interact to augment immune responses and prevent genetic damage and cancer. Nutrition. 1989;5:106110.
  • 44
    Das UN. Delta 6 desaturase as the target of the beneficial actions of magnesium. Med Sci Monit. 2010;16:LE11LE12.
  • 45
    Sonita B, Touyz RM. Magnesium transport in hypertension. Pathophysiology. 2007;14:205211.
  • 46
    Kisters K, Gremmler B, Hausberg M. Disturbed Mg++ transporters in hypertension. J Hypertens. 2008;26:24502451.
  • 47
    Yogi A, Callera GE, Antuens TT, et al. Vascular biology of magnesium and its transporters in hypertension. Magnes Res. 2010;23:207215.
  • 48
    Yoga A, Callera GE, Antunes TT, et al. Transient receptor potential melastatin 7 (TRPM7) cation channels, magnesium and the vascular system in hypertension. Circ J. 2011;75:237245.
  • 49
    Trapani V, Farruggia G, Marraccini C, et al. Intracellular magnesium detection: imaging a brighter future. Analyst. 2010;135:18551866.
  • 50
    Resnick L. The cellular ionic basis of hypertension and allied clinical condiditons. Prog Cardiovasc Dis. 1999;42(1):122.